|
1
|
Savage SA, Mirabello L, Wang Z,
Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R,
Andrulis IL, Wunder JS, et al: Genome-wide association study
identifies two susceptibility loci for osteosarcoma. Nat Genet.
45:799–803. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bonuccelli G, Avnet S, Grisendi G, Salerno
M, Granchi D, Dominici M, Kusuzaki K and Baldini N: Role of
mesenchymal stem cells in osteosarcoma and metabolic reprogramming
of tumor cells. Oncotarget. 5:7575–7588. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu J, Song G, Tang Q, Zou C, Han F, Zhao
Z, Yong B, Yin J, Xu H, Xie X, et al: IRX1 hypomethylation promotes
osteosarcoma metastasis via induction of CXCL14/NF-κB signaling. J
Clin Invest. 125:1839–1856. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garcia A and Singh H: Bevacizumab and
ovarian cancer. Ther Adv Med Oncol. 5:133–141. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rusckowski M, Wang Y, Blankenberg FG,
Levashova Z, Backer MV and Backer JM: Targeted scVEGF/(177)Lu
radiopharmaceutical inhibits growth of metastases and can be
effectively combined with chemotherapy. EJNMMI Res. 6:42016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoeben A, Landuyt B, Highley MS, Wildiers
H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth
factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zi FM, He JS, Li Y, Wu C, Wu WJ, Yang Y,
Wang LJ, He DH, Yang L, Zhao Y, et al: Fibroblast activation
protein protects bortezomib-induced apoptosis in multiple myeloma
cells through β-catenin signaling pathway. Cancer Biol Ther.
15:1413–1422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wikberg ML, Edin S, Lundberg IV, Van
Guelpen B, Dahlin AM, Rutegård J, Stenling R, Oberg A and Palmqvist
R: High intratumoral expression of fibroblast activation protein
(FAP) in colon cancer is associated with poorer patient prognosis.
Tumor Biol. 34:1013–1020. 2013. View Article : Google Scholar
|
|
10
|
Hua X, Yu L, Huang X, Liao Z and Xian Q:
Expression and role of fibroblast activation protein-alpha in
microinvasive breast carcinoma. Diagn Pathol. 6:1112011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu R, Li H, Liu L, Yu J and Ren X:
Fibroblast activation protein. Cancer Biol Ther. 13:123–129. 2014.
View Article : Google Scholar
|
|
12
|
Lai D, Ma L and Wang F: Fibroblast
activation protein regulates tumor-associated fibroblasts and
epithelial ovarian cancer cells. Int J Oncol. 41:541–550. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mentlein R, Hattermann K, Hemion C,
Jungbluth AA and Held-Feindt J: Expression and role of the cell
surface protease seprase/fibroblast activation protein-α (FAP-α) in
astroglial tumors. Biol Chem. 392:199–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuan D, Liu B, Liu K, Zhu G, Dai Z and Xie
Y: Overexpression of fibroblast activation protein and its clinical
implications in patients with osteosarcoma. J Surg Oncol.
108:157–162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao D, Pan C, Sun J, Gilbert C,
Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D,
et al: VEGF drives cancer-initiating stem cells through
VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene.
34:3107–3119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ishigami SI, Arii S, Furutani M, Niwano M,
Harada T, Mizumoto M, Mori A, Onodera H and Imamura M: Predictive
value of vascular endothelial growth factor (VEGF) in metastasis
and prognosis of human colorectal cancer. Br J Cancer.
78:1379–1384. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neufeld G, Cohen T, Gengrinovitch S and
Poltorak Z: Vascular endothelial growth factor (VEGF) and its
receptors. FASEB J. 13:9–22. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cross MJ, Dixelius J, Matsumoto T and
Claesson-Welsh L: VEGF-receptor signal transduction. Trends Biochem
Sci. 28:488–494. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kelly T, Huang Y, Simms AE and Mazur A:
Fibrobl Activation Protein-α: A key modulator of the
microenvironment in multiple pathologies. Int Rev Cell Mol Biol.
297:83–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia J, Martin TA, Ye L and Jiang WG: FAP-α
(Fibroblast activation protein-α) is involved in the control of
human breast cancer cell line growth and motility via the FAK
pathway. BMC Cell Biol. 15:162014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi M, Yu DH, Chen Y, Zhao CY, Zhang J,
Liu QH, Ni CR and Zhu MH: Expression of fibroblast activation
protein in human pancreatic adenocarcinoma and its
clinicopathological significance. World J Gastroenterol.
18:840–846. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Adeoye OO, Bouthors V, Hubbell MC,
Williams JM and Pearce WJ: VEGF receptors mediate hypoxic
remodeling of adult ovine carotid arteries. J Appl Physiol (1985).
117:777–787. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu Y, Huang A, Li T, Su X, Ding H, Li H,
Qin X, Hou L, Zhao Q, Ge X, et al: MiR-152 reduces human umbilical
vein endothelial cell proliferation and migration by targeting
ADAM17. FEBS Lett. 588:2063–2069. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sasore T and Kennedy B: Deciphering
combinations of PI3K/AKT/mTOR pathway drugs augmenting
anti-angiogenic efficacy in vivo. PLoS One. 9:e1052802014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khan KH, Yap TA, Yan L and Cunningham D:
Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J
Cancer. 32:253–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu LZ, Li C, Chen Q, Jing Y, Carpenter R,
Jiang Y, Kung HF, Lai L and Jiang BH: miR-21 induced angiogenesis
through AKT and ERK Activation and HIF-1α expression. PLoS One.
6:e191392011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang H, Wu Q, Liu Z, Luo X, Fan Y, Liu Y,
Zhang Y, Hua S, Fu Q, Zhao M, et al: Downregulation of FAP
suppresses cell proliferation and metastasis through PTEN/PI3K/AKT
and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death
Dis. 5:e11552014. View Article : Google Scholar : PubMed/NCBI
|
